Larotrectinib RAI Thyroid (LANTERN)

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion. The study involves taking a study drug called larotrectinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment).

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT05783323

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
22-020549
Official Title:
LArotrectiNib To Enhance RAI avidity in patients with differentiated thyroid cancer harboring NTRK fusions (LANTERN)
Study Phase:
Phase II
Eligible Age Range:
1 - 99 Years
Gender:
All
Study Categories:

Visit Criteria

Participants in the research will:

  • Receive a study drug called Larotrectinib
  • Complete frequent clinic visits at CHOP
  • Possibly delay standard of care RAI therapy
  • Have periodic imaging performed to evaluate response to treatment

Those who agree to participate in the optional imaging sub-study will:

  • Have an extra Whole Body Scan (WBS)
  • Consume a low iodine diet for 7-14 days before the WBS scan
  • Receive a drug called Thyrogen and receive a low dose of radioactive sodium iodine before the WBS scan